Viridian Therapeutics Is Ready For An Eventful 2026

Viridian Therapeutics, Inc. nears profitability and gears up for veligrotug’s 2025 launch. Click here to find out why VRDN ...

New lab-made antibody matches IVIG effectiveness at lower doses in mice

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat ...
The Malaysian Reserve

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to ...
Guyana Chronicle

Shi-Oil celebrates Ryan Rahaman’s South Dakota dominance

Shi-Oil, a locally-owned fuel importer and distributor, has extended heartfelt congratulations to Ryan Rahaman, who was ...

Study supports wider use of FDA-approved drug for rare muscle disease

UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, ...
News-Medical.Net on MSN

Engineered biomaterial promotes formation of cancer-fighting immune cell clusters

Researchers at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary ...
EurekAlert!

New study shows invasive Group A Streptococcus outcomes shaped by treatment strategies, not species lineage

A 15-year retrospective study in adults admitted to the intensive care department at Donostia University Hospital has revealed crucial insights into invasive Streptococcus pyogenes (iGAS) infections.